Hormonal
Metformin does not improve insulin-stimulated glucose uptake (insulin sensitivity) in individuals with type 2 diabetes; its primary mechanism is the suppression of lipolysis and reduction of free fatty acids, which enhances basal glucose clearance.
If you are taking metformin, do not expect it to 'fix' your insulin resistance in the sense of making your muscles more efficient at using insulin. Instead, it works by reducing the fat acids in your blood, which helps your body manage blood sugar at rest. This distinction is important for understanding why your insulin levels might drop without a corresponding change in how your muscles respond to high insulin levels.
Metformin treatment does not improve IMGU... Metformin treatment is generally believed to decrease hepatic glucose production... Instead, Abbasi et al. [15,16] showed that metformin treatment decreases free fatty acid (FFA) concentrations at basal insulin concentrations and increases metabolic clearance rate of glucose. They hypothesized that metformin suppresses lipolysis during fasting and thus enhances glucose clearance at basal insulin concentrations.
Why this rating
Based on multiple cited studies using rigorous methods like hyperinsulinemic clamps and insulin suppression tests.
Source
Myths about Insulin Resistance: Tribute to Gerald Reaven
Sun H. Kim et al. · Endocrinology and Metabolism · 2019
DOI 10.3803/enm.2019.34.1.47
More from this paper
- Waist circumference does not predict insulin resistance better than body mass index (BMI); both measures are similarly correlated with insulin resistance.Good
- Insulin resistance does not prevent weight loss; insulin-resistant individuals lose weight to the same degree as insulin-sensitive individuals when following a hypocaloric diet.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →